title: Toxicity and compliance with a chemoradiotherapy schedule for advanced nasopharyngeal carcinoma: a single institution experience using the Intergroup 0099 study regimen.
authors.forename: Enrique A
authors.initials: EA
authors.lastname: Chajón
authors.forename: Maria Isabel
authors.initials: MI
authors.lastname: García-Berrocal
authors.forename: Cristina
authors.initials: C
authors.lastname: De la Fuente
authors.forename: Carlos
authors.initials: C
authors.lastname: Regueiro
authors.forename: Jesús
authors.initials: J
authors.lastname: Romero
authors.forename: Francisco
authors.initials: F
authors.lastname: Valcárcel
authors.forename: Rosa
authors.initials: R
authors.lastname: Magallón
authors.forename: Raúl
authors.initials: R
authors.lastname: Hernanz
authors.forename: Alejandro
authors.initials: A
authors.lastname: De la Torre
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001071:Appointments and Schedules; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D010349:Patient Compliance / Q000706:statistics & numerical data*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome